Pfizer’s Post

Need to include zero growth in over 25 years! A stock price going from 60 dollars down to less than 28 dollars in one year which is the same as it was over 25 years! A dismal job considering all the profits pfizer has generated over decades especially over the covid period. It will be interesting to see what the compensation and bonuses will be for all these executives/ceo this year!Embarrassing! When comparing to Eli Lilly over the years. How is it possible that we failed in developing a weight drug in-house and furthermore not buy a company or make an agreement to co-develop a weight drug. Where is the accountability! It should start at the top not from the hard working scientists that have lost their jobs in the last 1-2 years. Please, stop sugar coating and talk/post more about what you are doing to create growth and WHY we are not seeing growth with all these figures and accomplishments that are posted year after year?

Coming to you live from JPM. I am excited to be in San Francisco at the 2024 JP Morgan Healthcare Conference to connect with clients and colleagues about the challenges and opportunities impacting our industry. Business model reinvention continues to be a significant theme—and it’s the focus of our new report, “Next in pharma 2024: Reinventing for returns.” Check it out to learn more about the key strategies pharma leaders should consider in the coming year. #JPM2024 https://pwc.to/3TRBFz6

#CPG manufacturers, be prepared for the aggressive M&A market shaping up for 2025 and 2026. Various industries will feel the impact: ✔ #Technology: Expect increased M&A activity as tech companies integrate new technologies into consumer products, especially health and wellness tech. ✔ #Retail: Retailers may merge with niche brands to meet evolving consumer demands and enhance competitiveness. ✔ #Pharmaceuticals: With a focus on health and wellness, pharma companies will likely expand into consumer health products through acquisitions. ✔ #LogisticsandSupplyChain: Consolidation will drive the need for more efficient solutions, leading to potential M&A in this sector. ✔ #Agriculture: To align with consumer trends, agribusinesses may acquire innovative farming solutions. ✔ #FinancialServices: Banks and financial institutions will play a crucial role in providing capital and advisory services for these transactions. These industries face significant changes due to the evolving M&A landscape. If you seek solutions in this dynamic environment, reach out to me. Michelle M.. I am here to assist you and be your strategic partner in navigating these opportunities. I have a world wide team & network that stands ready to help you in anything within manufacturing, warehousing, logistics, transportation, reassembly, tear downs, 911 support. #MandA #BusinessGrowth #cpg #automate #industrialmanufacturingandsolutions #needhelp?

Delve into 'Which Is a Better Investment, AbbVie Inc or HALEON PLC - ADR Stock?' for a comparative analysis. With A+ Investor, explore key metrics like Value, Quality, and Estimate Revisions to make informed investment decisions. #Investing READ: https://ow.ly/pcnE50QK4hr

Delve into 'Which Is a Better Investment, AbbVie Inc or HALEON PLC - ADR Stock?' for a comparative analysis. With A+ Investor, explore key metrics like Value, Quality, and Estimate Revisions to make informed investment decisions. #Investing READ: https://ow.ly/pcnE50QK4hr

Who would have bet last January (beyond me of course 😉) on an old established British manufacturing based business as the best investment in Europe in 2023? Fact is: Rolls-Royce is the best performing stock on FTSE100 and StoxxEuro600 in 2023. By far. Beating the more visible trend setters: fat-killing pharma and GenAI. Engines makes the world go faster. Thanx to its people and technologies and a focused no-nonsense strategy.

M&A - first 2024 half saw an increased level of M&A transactions which was welcome by the biotech ecosystem. I took the opportunity of the first holiday days to dive again into this book. It reminded me that identifying key values drivers is not enough for successful M&A. The secret resides in identifying business dilemmas and what makes unique each organization. By reconciling those dilemmas, sustainable values drivers for the new entity will arise and need to be included in the business case. To do so, the ability to go beyond financial projections is a skill needed to those who want to dance the M&A tango. The reading reminded me the Ferring Rebiotix M&A with an aspirational leader inviting all of us in the project to focus on differences. A must read book!

CR3's NxGen Profile of the Month is Kyler Merck, a Manager with our Chicago team. Kyler is versed in evaluating prospective investment opportunities, as well as the valuation and financial modeling of existing investments and businesses. Read more about Kyler: https://lnkd.in/gFidSCpE #nextgen #restructuring #turnaround #turnaroundmanagement

2024 is rapidly shaping up to be an outstanding year for private equity deal activity with both TPG and KKR now pointing to a strong funnel of H2 activity. The life science tools and pharma services markets in particular provide an excellent entry point with multiple technology and market disruption opportunities along the biopharma value chain. #sustainability #PrivateEquity #SocialImpact #biopharma #biomaterials

In healthcare, packaging performance is essential to protect expensive, critical items like medical devices and specialty therapeutics while ensuring safe, on-time delivery to patients. The intersection of sustainability and performance is creating growth opportunities for innovators in the space—themes that were top of mind throughout WestPack at MD&M West 2024. The latest article from our Industrials Group shares key takeaways from the event and how they’re impacting the packaging sector’s M&A opportunities. #MDMWest #WestPack